Abstracts liver disease. Literature review was performed to obtain other probabilities for the model. The effectiveness measure was the number of patients immune to both HAV and HBV. RESULTS: The selective strategy was less costly but less effective with a cost-effectiveness ratio of $105 per patient immune to HAV& HBV. The universal strategy was more effective but more expensive with a cost-effectiveness ratio of $112 per patient immune to HAV& HBV. Compared with the selective strategy, universal strategy was associated with an incremental costeffectiveness (ICE) ratio of $154 per additional patient immune to HAV and HBV. The universal strategy would become more cost-effective if the cost of combined vaccine reduces by >9.7% to <$0.75, if the cost of HBV vaccine increases by >25% to >$34.50, if the cost of blood tests for immunity increases by >23% to >$25.25, or if the prevalence of anti-HBs decreases to <24%. CONCLUSIONS: The selective vaccination strategy for HAV and HBV in our sample of patients with HCV is more cost-effective. However, the ICE for the universal strategy is minimal. 3 Hoffmann-La Roche, Nutley, NJ, USA Peginterferon alfa-2a (40KD) (PEGASYS®), a new treatment option for patients infected with chronic hepatitis B (CHB), offers improved efficacy with a defined treatment duration compared with lamivudine (LAM), but at a higher cost. OBJECTIVE: To assess the clinical outcomes, costs and costeffectiveness of PEGASYS for the treatment of patients with HBeAg-negative CHB, compared to LAM treatment for one-year and four-years. METHODS: A cost-effectiveness analysis from the UK National Health Service (NHS) perspective using a statetransition Markov model simulating the natural history of HBeAg-negative CHB. Efficacy data were obtained from a recent, randomized clinical trial comparing PEGASYS and LMV in patients with HBeAg-negative CHB. Patients: Hypothetical cohort of 40-year old patients with HBeAg-negative CHB. Interventions: PEGASYS and LAM monotherapy. Measurements: Life expectancy, quality-adjusted life expectancy, lifetime costs, and incremental cost-effectiveness ratios (ICERs). RESULTS: Fortyeight week treatment with PEGASYS compared to LAM resulted in higher total costs, but greater quality-adjusted life expectancy, yielding an ICER of £5047/quality-adjusted life year (QALY) gained. Although there is uncertainty associated with the prognosis of HBeAg-negative CHB, the ICER did not exceed £10,000/QALY gained despite variation in each parameter used in the analysis. In the analysis comparing 48-week treatment with PEGASYS to 208-week treatment with LAM, the ICER was £2767/QALY gained. CONCLUSIONS: Short-term treatment with PEGASYS compared to either short-term or long-term LAM treatment in CHB patients who are HBeAg-negative appears to offer life expectancy benefits at a cost-effectiveness ratio comparable to other currently reimbursed pharmaceutical interventions.
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COST-EFFECTIVENESS OF PEGINTERFERON ALFA-2A (40KD) COMPARED TO LAMIVUDINE FOR THE TREATMENT OF E ANTIGEN NEGATIVE CHRONIC HEPATITIS B IN THE UK
Veenstra DL 1 , Sullivan SD 1 , Lewis G 2 , Green J 3 1 University of Washington, Seattle, WA, USA; 2 Roche Products Limited, Welwyn Garden City, Herts, UK;
3 Hoffmann-La Roche, Nutley, NJ, USA Peginterferon alfa-2a (40KD) (PEGASYS®), a new treatment option for patients infected with chronic hepatitis B (CHB), offers improved efficacy with a defined treatment duration compared with lamivudine (LAM), but at a higher cost. OBJECTIVE: To assess the clinical outcomes, costs and costeffectiveness of PEGASYS for the treatment of patients with HBeAg-negative CHB, compared to LAM treatment for one-year and four-years. METHODS: A cost-effectiveness analysis from the UK National Health Service (NHS) perspective using a statetransition Markov model simulating the natural history of HBeAg-negative CHB. Efficacy data were obtained from a recent, randomized clinical trial comparing PEGASYS and LMV in patients with HBeAg-negative CHB. Patients: Hypothetical cohort of 40-year old patients with HBeAg-negative CHB. Interventions: PEGASYS and LAM monotherapy. Measurements: Life expectancy, quality-adjusted life expectancy, lifetime costs, and incremental cost-effectiveness ratios (ICERs). RESULTS: Fortyeight week treatment with PEGASYS compared to LAM resulted in higher total costs, but greater quality-adjusted life expectancy, yielding an ICER of £5047/quality-adjusted life year (QALY) gained. Although there is uncertainty associated with the prognosis of HBeAg-negative CHB, the ICER did not exceed £10,000/QALY gained despite variation in each parameter used in the analysis. In the analysis comparing 48-week treatment with PEGASYS to 208-week treatment with LAM, the ICER was £2767/QALY gained. CONCLUSIONS: Short-term treatment with PEGASYS compared to either short-term or long-term LAM treatment in CHB patients who are HBeAg-negative appears to offer life expectancy benefits at a cost-effectiveness ratio comparable to other currently reimbursed pharmaceutical interventions. Patients were required to have one claim for any proton pump inhibitor (esomeprazole, lansoprazole, omeprazole, pantoprazole, rabeprazole) and an antibiotic combination of amoxicillin/clarithromycin (AC) or metronidazole/tetracycline (MT). Treatment patterns were evaluated along with re-treatment rates (regimen effectiveness), testing rates, and pharmaceutical expenditures. RESULTS: In total, 10,203 patients were identified; the average patient age was 52.8 years, the majority of patients were female, 41.6% had privately funded insurance and 58.4% had publicly funded insurance. The majority of patients were naïve to H. pylori eradication therapy over the 12 months prior to initial therapy and 92.6% of patients received AC as their antibiotic combination. Fourteen-day triple therapy (PPI + two antibiotics) was prescribed for majority (80%) of patients regardless of H. pylori eradication therapy treatment history. Re-treatment rates did not vary significantly among different triple therapy treatment regimen durations: 7.8% for seven day, 7.6% for ten day, and 7.9% for 14 day regimens. However, the cost of initial treatment for the different treatment durations varied widely, $120.82 for seven day regimens, $178.79 for ten day regimens, and $294.49 for 14 day regimens. CONCLUSION: This study found significant differences in treatment costs by duration of therapy despite similar re-treatment rates among different lengths (seven day vs. 14 day) of H. pylori triple therapy regimens. There are potential economic benefits realized in shorter duration of treatment, as measured by the direct expenditures on the medications themselves, and associated re-treatment and testing expenditures.
PGI6 UTILIZATION, RE-TREATMENT, AND COST OF DIFFERING LENGTHS OF H. PYLORI TREATMENT REGIMENS FROM US HEALTH CARE CLAIMS DATABASES
PGI7 MANAGING CROHN'S DISEASE: USE AND COST OF INPATIENT, EMERGENCY DEPARTMENT AND OBSERVATION UNIT SERVICES DURING ONE YEAR
O'Brien J, Pitoniak-Morse C Caro Research Institute, Concord, MA, USA OBJECTIVE: Crohn's disease (aka: inflammatory bowel disease, regional enteritis) is a chronic autoimmune disorder that can occur at any age. This analysis examined use and cost of hospitalizations, observation unit (OU) stays and emergency department (ED) visits during a one-year period by patients with Crohn's disease. METHODS: Using 2001-2002 Massachusetts ED, OU and inpatient data, a cohort was identified by personal identifiers and ICD-9 principal diagnosis codes (555.0-555.9 ). An encounter profile was established for each patient starting with the first stay or visit at any hospital, ED or OU in Massachusetts in 2001. From that index encounter, each contact for regional enteritis was tracked for 12 months for that patient. Cost estimates, reported in 2004 USD, include accommodations and ancillary services. Charges were adjusted using a 0.55 costto-charge ratio and appropriate inflation indices. RESULTS: A
